SCHEMBL13135643

SCHEMBL13135643

CN1CCN(c2ccnn2-c2ccc(F)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
NPC1 O15118 1/20 0.49
TP53 P04637 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPK14 Q16539 1/20 0.43
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
BLM P54132 1/20 0.42
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
HPGD P15428 2/20 0.41
GAA P10253 2/20 0.41
GLA P06280 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 3/20 0.40
HRH4 Q9H3N8 1/20 0.40
POLB P06746 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13135640 0.83 POLB (0.50) LMNASMN1; SMN2KMT2AGAAPOLB
SCHEMBL2857088 0.83 HTR1A (0.44) TP53HTR6
SCHEMBL13135645 0.77 MAPT (0.52) LMNANPC1TP53RAB9ASMN1; SMN2
SCHEMBL1375430 0.77 LMNA (0.73) LMNANPC1TP53RAB9ASMN1; SMN2
SCHEMBL25802996 0.70 LMNA (0.65) LMNANPC1TP53RAB9ASMN1; SMN2
SCHEMBL13734675 0.70 NPC1 (0.47) NPC1RAB9ASMN1; SMN2KMT2AALDH1A1
SCHEMBL15779574 0.70 OXTR (0.48) LMNANPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL11943538 0.69 ALDH1A1 (0.62) LMNATP53RAB9ASMN1; SMN2KMT2A
SCHEMBL9682530 0.68 KHK (0.51) LMNANPC1TP53RAB9ASMN1; SMN2
SCHEMBL9681940 0.68 KHK (0.48) LMNANPC1TP53RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 LMNA 4632/4885NPC1 1300/4885TP53 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.